2025
Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study
Yegya-Raman N, Plastaras J, Wright C, Chelius M, Zhang S, Baron J, Hubbeling H, Sim A, Robinson T, Jain M, Imber B, Fregonese B, Yahalom J, Ladbury C, Dandapani S, Pinnix C, Gunther J, Fang P, Wu S, Dabaja B, Yang J, Chew J, Braunstein S, Sinha S, Delinger N, Sun S, Terezakis S, Sakthivel G, Constine L, Chowdhry A, Reagan P, Burke S, Tseng Y, LaRiviere M, Maity A, Schuster S, Chong E, Figura N. Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study. Blood Advances 2025, 9: 3293-3303. PMID: 40203192, DOI: 10.1182/bloodadvances.2025015855.Peer-Reviewed Original ResearchConceptsChimeric antigen receptor T-cell therapyImmune effector cell-associated neurotoxicity syndromeSuperior progression-free survivalProgression-free survivalB-cell lymphomaCytokine release syndromeAssociated with superior progression-free survivalOverall survivalTwo-year progression-free survivalChimeric antigen receptor T cellsLactate dehydrogenaseRelapsed/refractory B-cell lymphomaLactate dehydrogenase normalizationAmerican Society for TransplantationT-cell therapyBaseline lactate dehydrogenaseMedian follow-upRetrospectively reviewed patientsAdvanced-stage diseaseHigh-risk cohortAxicabtagene ciloleucelBrexucabtagene autoleucelSystemic therapyMulticenter studyT cellsIntratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor-resistant tumors resulting in complete responses
Lakshmipathi J, Santha S, Li M, Qian Y, Roy S, Luheshi N, Politi K, Bosenberg M, Eyles J, Muthusamy V. Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor-resistant tumors resulting in complete responses. Cancer Immunology, Immunotherapy 2025, 74: 250. PMID: 40560386, PMCID: PMC12198101, DOI: 10.1007/s00262-025-04105-0.Peer-Reviewed Original ResearchConceptsAnti-tumor immune responseTumor-associated macrophagesCytotoxic T cellsImmune responseActivity of checkpoint inhibitorsAnti-PD-L1 antibodyPhagocytosis of tumor cellsAnti-PD-L1Enhanced anti-tumorAntigen presentation machineryCell-based immune responsesMurine tumor modelsTh1-type cytokinesColorectal carcinoma tumorsICI resistanceMurine IL12Checkpoint inhibitorsPresentation machineryIntratumoral deliveryResistant tumorsAdvanced diseaseCarcinoma tumorsTumor microenvironmentMurine tumorsT cellsLung adenocarcinoma-derived IFN-γ promotes growth by modulating CD8+ T cell production of CCR5 chemokines
Kratzmeier C, Taheri M, Mei Z, Lim I, Khalil M, Carter-Cooper B, Fanaroff R, Ong C, Schneider E, Chang S, Leyder E, Li D, Luzina I, Banerjee A, Krupnick A. Lung adenocarcinoma-derived IFN-γ promotes growth by modulating CD8+ T cell production of CCR5 chemokines. Journal Of Clinical Investigation 2025 PMID: 40553564, DOI: 10.1172/jci191070.Peer-Reviewed Original ResearchCD8+ T cellsIFN-gCCR5 chemokinesT cellsCD4+Foxp3+ T regulatory cellsCD8+ T-cell productionCancer cellsHuman lung cancer patientsLevels of IFN-gT regulatory cellsMurine lung adenocarcinomaLung adenocarcinoma modelLung cancer patientsMechanisms of immunoregulationCell line modelsLung cancer cellsTumor bedAdenocarcinoma modelTh1 cytokinesTumor microenvironmentImmunological environmentImmunoregulatory pathwaysCarcinogen-inducedTumor growthLung cancerEvaluating the immunogenicity of a mouse partial hindlimb for composite allotransplantation
Sun J, Ligi S, Biniazan F, Haykal S. Evaluating the immunogenicity of a mouse partial hindlimb for composite allotransplantation. Frontiers In Immunology 2025, 16: 1595319. DOI: 10.3389/fimmu.2025.1595319.Peer-Reviewed Original ResearchPost-operative day 7CD8+ T cellsTr1 cellsVascularized composite allotransplantationAcute rejectionT cellsAllogeneic skinImmune responseTransplantation modelIncreased CD8+ T cellsImproving long-term graft survivalRecipient-derived T cellsFlow cytometryLong-term graft survivalPhenotype of infiltrating cellsImmune response complexityTolerance induction strategiesIncreased risk of infectionImmune cell populationsT cell presenceTUNEL-positive cellsInvestigate immune responsesSevere tissue traumaImmunosuppressive approachesSubclinical rejectionAn evaluation of denileukin diftitox for the treatment of relapsed or refractory cutaneous T-cell lymphoma
Goyal A, Foss F. An evaluation of denileukin diftitox for the treatment of relapsed or refractory cutaneous T-cell lymphoma. Expert Opinion On Biological Therapy 2025, ahead-of-print: 1-8. PMID: 40489974, DOI: 10.1080/14712598.2025.2517853.Peer-Reviewed Original ResearchConceptsDenileukin difitoxResponse rateRefractory cutaneous T-cell lymphomaCutaneous T-cell lymphomaPlaque stage diseaseCells expressing CD25Adverse Events gradeCapillary leak syndromeElevated hepatic transaminasesImmunoregulatory T cellsT-cell lymphomaExpressing tumor cellsDiphtheria toxin AMultiple mechanisms of actionHigh response rateSezary syndromeInfusion reactionsCD25 expressionDenileukin diftitoxMycosis fungoidesStage diseaseHepatic transaminasesMechanism of actionT cellsIL-2Mitochondrial DNA Haplogroups, Biomarkers of Inflammation and Immune Activation, and Risk of Diabetes in Veterans With and Without Human Immunodeficiency Virus
Yan A, Kundu S, Samuels D, Bailin S, Xu K, So-Armah K, Butt A, Gerschenson M, Goetz M, Doyle M, Tracy R, Marconi V, Justice A, Freiberg M, Koethe J, Hulgan T. Mitochondrial DNA Haplogroups, Biomarkers of Inflammation and Immune Activation, and Risk of Diabetes in Veterans With and Without Human Immunodeficiency Virus. The Journal Of Infectious Diseases 2025, jiaf304. PMID: 40488298, DOI: 10.1093/infdis/jiaf304.Peer-Reviewed Original ResearchHaplogroup L3MtDNA haplogroupsCD4+ T cellsAssociated with incident DMVeterans Aging Cohort StudyBlack PWHT cellsMitochondrial DNA haplogroupsIncident DMHaplogroupsWomen of African ancestryVeterans Aging Cohort Study participantsHaplogroup associationsT-cell phenotypeHuman immunodeficiency virusType 2 diabetes mellitusSerum IL-6Associated with DMBiomarkers of inflammationCellular immune biomarkersAging Cohort StudyRisk of diabetesDM outcomesGenome-wide genotypingCD28-negativeRole of Chimeric Antigen Receptor–Expressing Cell Therapy in Immune-Mediated Kidney Diseases: A Review
Peng J, Zhang Y, Wang J, Zhang H, Schett G. Role of Chimeric Antigen Receptor–Expressing Cell Therapy in Immune-Mediated Kidney Diseases: A Review. American Journal Of Kidney Diseases 2025 PMID: 40484342, DOI: 10.1053/j.ajkd.2025.04.012.Peer-Reviewed Original ResearchImmune-mediated kidney diseasesB-cell depletionB cellsKidney diseaseCell therapyPlasma cellsTreatment of immune-mediated kidney diseasesB-cell-depleting monoclonal antibodyB-cell targeted therapiesComplete B-cell depletionAutoantibody-producing plasma cellsDeplete plasma cellsMonoclonal antibodiesAntigen-presenting cellsAdaptive immune responsesImmune-mediatedSelf-antigensT cellsImmune cellsImmune responseTherapyInfiltrated tissuesDiseaseAntibodiesCellsMHC class I expression and outcomes in breast cancer in the real-world clinico-genomic data and the FinXX trial.
Liu Y, Deshmukh S, Ma Y, Carter J, Wu S, Xiu J, Norton N, Ruddy K, Ruddy K, Perez E, Gandhi S, Barreto Coelho P, Lustberg M, Goetz M, Joensuu H, Sledge G, Thompson E, Chumsri S. MHC class I expression and outcomes in breast cancer in the real-world clinico-genomic data and the FinXX trial. Journal Of Clinical Oncology 2025, 43: 570-570. DOI: 10.1200/jco.2025.43.16_suppl.570.Peer-Reviewed Original ResearchTriple-negative BCMHC-I expressionCD8+ T cellsHER2+Overall survivalI expressionBC subtypesBreast cancerMHC-IT cellsHLA-CAssociated with higher immune infiltrationDownregulation of MHC-I expressionFrequency of PD-L1 positivityHLA-AHLA-BT cell inflamed scoreExpression of HLA-AInfiltration of B cellsMHC class I expressionSubtypes of breast cancerMechanisms of immune evasionReal-world overall survivalHormone receptor-positivePD-L1 positivityPOS1002 ALTERED GUT MICROBIOTA COMPOSITION IN AUTOIMMUNE DISEASE PATIENTS UNDERGOING CD19-CAR T-CELL THERAPY
Maeda Y, Wirtz S, Hagen M, Rothe T, Wirsching A, Grieshaber-Bouyer R, Gimaev I, Schmid E, Kriegel M, Müller F, Mackensen A, Schett G, Zaiss M. POS1002 ALTERED GUT MICROBIOTA COMPOSITION IN AUTOIMMUNE DISEASE PATIENTS UNDERGOING CD19-CAR T-CELL THERAPY. Annals Of The Rheumatic Diseases 2025, 84: 1114-1115. DOI: 10.1016/j.ard.2025.06.357.Peer-Reviewed Original ResearchCD19 CAR T-cell therapyCD19 CAR-T cellsT-cell therapySystemic lupus erythematosusIdiopathic inflammatory myopathiesFecal IgA levelsCD19-CART cellsSerum IgA levelsAutoimmune diseasesIgA levelsSystemic sclerosisGut microbiota compositionLupus erythematosusInfusion of CD19-CAR T cellsChimeric antigen receptor (CAR)-T cellsTransfection of T cellsSevere systemic lupus erythematosusStreptococcus speciesFecal IgA contentSecond-generation CARDrug-free remissionLong-term remissionPathogenesis of autoimmune diseasesMicrobiota compositionImmune biomarkers as predictors of response to mosunetuzumab in previously untreated follicular (FL) and marginal zone lymphoma (MZL).
Milrod C, Chorzalska A, Morgan J, Pardo M, Raker C, Ollila T, Pelcovits A, McMahon J, Donnelly S, Carmody C, Dallesandro F, Matasar M, Huntington S, Dubielecka P, Olszewski A. Immune biomarkers as predictors of response to mosunetuzumab in previously untreated follicular (FL) and marginal zone lymphoma (MZL). Journal Of Clinical Oncology 2025, 43: 7063-7063. DOI: 10.1200/jco.2025.43.16_suppl.7063.Peer-Reviewed Original ResearchMarginal zone lymphomaCTLA-4 levelsComplete responseT cell activationCTLA-4T cellsImmune biomarkersNK cellsCytokine levelsInvestigator-initiated phase 2 trialMarkers of T-cell activationEffector memory T-cell subsetsIndolent B-cell lymphomaCD8+ T cellsMemory T cell subsetsInvestigation of combination therapyFlow cytometryCD8+ subsetsBaseline cytokine levelsCirculating NK cellsB-cell lymphomaT cell subsetsImmune cell subsetsMultiplex Luminex assaySystemic immune changesP-470 Endometrial immune cell profiles differ during fresh vs. frozen embryo transfer cycles: insights into the window of implantation
Strbo N, Rodriguez S, Padula L, Fisher E, Slater B, Gharagozloo A, Awadallah C, Ibrahim M, Rubino R, Paidas M, Attia G. P-470 Endometrial immune cell profiles differ during fresh vs. frozen embryo transfer cycles: insights into the window of implantation. Human Reproduction 2025, 40: deaf097.776. DOI: 10.1093/humrep/deaf097.776.Peer-Reviewed Original ResearchFrozen embryo transfer cyclesFrozen embryo transferImmune cell profilesTime of embryo transferEmbryo transferFrozen cyclesEndometrial milieuWindow of implantationT cellsAssisted reproductive technology cyclesEndometrial expressionFresh embryo transferImprove IVF outcomesCell profilesAcademic fertility centerImmune milieuImmune cellsExpression of CD8+ T cellsAntagonist protocolCD8+ T cellsExpression of B cellsGonadotropin doseCycle outcomesExpression of T cellsIVF outcomesInvestigating practice patterns in bone marrow biopsies for cutaneous T-cell lymphoma: A multicenter clinician survey.
Rashid S, Kim E, Slavinsky V, Sun Y, Pierog O, Gru A, Foss F, Rozati S. Investigating practice patterns in bone marrow biopsies for cutaneous T-cell lymphoma: A multicenter clinician survey. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.e19075.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaBone marrow biopsyT-cell lymphomaMarrow biopsyManagement of cutaneous T-cell lymphomaPrognosis of cutaneous T-cell lymphomaBone marrow biopsy findingsPractice patternsAdvanced disease stageFisher's exact testUnexplained hematologic abnormalitiesInvestigate practice patternsEvidence-based guidelinesPET-CTStaging purposesExtracutaneous involvementPrognostic implicationsT cellsHematologic abnormalitiesSystem involvementAltered managementDifferential diagnosisExact testDisease stagePatient managementImpact of peritoneal macrophage depletion on endometriotic lesion development in a mouse model
Stratopoulou C, Cacciottola L, Gawde N, Ngombo A, Brusa D, Donnez J, Taylor H, Dolmans M. Impact of peritoneal macrophage depletion on endometriotic lesion development in a mouse model. Journal Of Endometriosis And Uterine Disorders 2025, 10: 100113. DOI: 10.1016/j.jeud.2025.100113.Peer-Reviewed Original ResearchMacrophage depletionEndometriotic lesionsTreated miceMacrophage accumulationMouse modelVascular endothelial growth factor immunostainingEndometriosis developmentQuantification of immune cellsFlow cytometryMouse model of endometriosisClodronate-containing liposomesKi67-positive proliferating cellsNovel therapeutic optionsRate of fibrosisModel of endometriosisTUNEL-positive apoptotic cellsLevels of fibrosisPathogenesis of endometriosisReproductive-age womenMasson's trichrome stainingEndometriotic lesion developmentEnhanced cell deathPlacebo-controlledUterine fragmentsT cellsUpdate on Acute Tubulointerstitial Nephritis: Clinical Features, Immunologic Insights, and Diagnostic and Treatment Approaches
Sahutoglu T, Perazella M. Update on Acute Tubulointerstitial Nephritis: Clinical Features, Immunologic Insights, and Diagnostic and Treatment Approaches. Kidney International Reports 2025, 10: 1643-1656. DOI: 10.1016/j.ekir.2025.03.050.Peer-Reviewed Original ResearchAcute tubulointerstitial nephritisAcute kidney injuryC-reactive proteinAcute kidney diseaseTubulointerstitial nephritisType IV hypersensitivity mechanismKidney diseaseAcute kidney injury etiologyTh2-mediated immune responsesSerum C-reactive proteinTriggered by medicationsTumor necrosis factor (TNF)-aInterleukin (IL)-9Urinary retinol-binding proteinT helper (Th)1T cell polarizationIrreversible kidney damageInflammatory endotypesImprove patient outcomesPrompt diagnosisKidney biopsyT cellsClinical featuresDiagnostic challengeImmune heterogeneityLatent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes
Lledó-Delgado A, Preston-Hurlburt P, Higdon L, Hu A, James E, Lim N, Long S, McNamara J, Nguyen H, Serti E, Sumida T, Herold K. Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes. Nature Communications 2025, 16: 5033. PMID: 40447640, PMCID: PMC12125364, DOI: 10.1038/s41467-025-60276-5.Peer-Reviewed Original ResearchConceptsCD8+ T cellsEBV-seropositive individualsType 1 diabetesT cellsImmune cellsAntigen-specific CD8+ T cellsDiagnosis of type 1 diabetesEBV-seronegative patientsEBV-seropositive patientsT cell activation pathwaysRegulatory T cellsAnti-CD3 mAbInnate immune cellsPeripheral blood cellsT cell receptorProgression of diseaseContext of type 1 diabetesImpaired signaling pathwaysTeplizumabClinical trialsLatent EBVBlood cellsSingle cell transcriptomicsModulate progressionMTOR signalingEvaluation of tumor immune microenvironment in Hispanic and African American breast cancer.
Hsu R, Deshmukh S, Rallos E, Al-zubeidy B, Martynova A, Stewart D, Jayachandran P, Spicer D, Wu S, Xiu J, Sledge G, Gandhi S, Chumsri S, Leone J, Mahtani R, Sandoval Leon A, Lustberg M, Roussos Torres E. Evaluation of tumor immune microenvironment in Hispanic and African American breast cancer. Journal Of Clinical Oncology 2025, 43: 1051-1051. DOI: 10.1200/jco.2025.43.16_suppl.1051.Peer-Reviewed Original ResearchTumor immune microenvironmentPrimary breast cancerCD8+ T cellsBreast cancerT cellsPD-L1Non-Hispanic whitesOverall survivalImmune microenvironmentIFN-gammaInflamed tumor immune microenvironmentAdvanced-stage breast cancerReal-world overall survivalEarly-stage BCImmune cell fractionsM2-like macrophagesMann-Whitney U testAfrican American breast cancerKaplan-Meier estimatesAA tumorsHER2+TMB-highPBC casesBC patientsImmune cellsMultiomic profiling of LRRC15 in triple negative breast cancer (TNBC).
Morgenstern Kaplan D, Deshmukh S, Wu S, Xiu J, Lopes G, Valdes F, King T, George S, Hurley J, Salazar A, Sucre S, Trapani D, Advani P, Jayachandran P, Lustberg M, Sledge G, Barreto Coelho P. Multiomic profiling of LRRC15 in triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2025, 43: 1098-1098. DOI: 10.1200/jco.2025.43.16_suppl.1098.Peer-Reviewed Original ResearchTriple negative breast cancerCancer-associated fibroblastsImmune cell fractionsH tumorsOverall survivalTumor microenvironmentT cellsHigher expression of immune checkpoint genesAbundance of cancer-associated fibroblastsTNBC heterogeneityExpression of immune checkpoint genesIncreased CAFsT cell inflamed scoreAssociated with better OSCD8+ T cellsInfiltration of B cellsReal-world overall survivalAnalysis of immune cellsFrequency of PIK3CAPositive predictive biomarkerPD-L1 positivityAssociated with poor prognosisImmune checkpoint genesTreatment-related survivalAdverse prognostic biomarkerPerturbational single-cell RNA sequencing of patient tumors in Merkel cell and small cell lung carcinomas.
Perry C, Frey A, Fei Y, Costa P, Wang J, Ghadermarzi S, Levine D, Koda A, Nassar A, Ding M, Nie Y, Cordero-Dumit T, Augert A, van Djik D, Olino K, Ishizuka J. Perturbational single-cell RNA sequencing of patient tumors in Merkel cell and small cell lung carcinomas. Journal Of Clinical Oncology 2025, 43: 2520-2520. DOI: 10.1200/jco.2025.43.16_suppl.2520.Peer-Reviewed Original ResearchSmall cell lung cancerMerkel cell carcinomaMonocyte-derived DCCD14+ monocytesT cellsPatient tumorsResponse to IFNImpact of immune checkpoint blockadeTumor-infiltrating T cellsCo-cultureSmall cell lung carcinomaTumor immunity cycleImmune checkpoint blockadeImmune cells co-culturedCell lung carcinomaInnate immune signaturesHuman tumor specimensCell lung cancerLymph node metastasisCell linesFactors associated with responseLong-term survivalAssociated with nonresponseStandard of careImmune samplesInfection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: Real-world analysis from CIBMTR
Wudhikarn K, Herr M, Chen M, Martens M, Baird J, Gowda L, Rangarajan H, Abid M, Kharfan-Dabaja M, Williams K, Ganguly S, Young J, Sharma A, Fatobene G, Jain T, Kanakry C, Modi D, Grover N, Salem B, Batista M, Vergidis P, Yin D, Beitinjaneh A, Kelkar A, Nishihori T, Holter-Chakrabarty J, Gergis U, Smith M, El Boghdadly Z, Dandoy C, Murthy H, Huppler A, Perales M, Chemaly R, Hill J, Riches M, Auletta J. Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: Real-world analysis from CIBMTR. Blood Advances 2025 PMID: 40435511, DOI: 10.1182/bloodadvances.2025016141.Peer-Reviewed Original ResearchCD19 chimeric antigen receptorT-cell therapyCD19 chimeric antigen receptor T-cell therapyInfection-related mortalityCD19 CAR-T cellsCAR-T cellsT cellsSevere immune effector cell-associated neurotoxicity syndromeChimeric antigen receptor T-cell therapyImmune effector cell-associated neurotoxicity syndromeCD19 CAR T-cell therapyCAR-T cell therapySevere cytokine release syndromeRisk factorsChimeric antigen receptorInferior overall survivalMedian follow-upB-cell lymphomaCytokine release syndromeIndependent risk factorCause of morbidityDays post-infusionIncidence of infectionOutcome of infectionIncreased infection riskThe subfornical organ is a nucleus for gut-derived T cells that regulate behaviour
Yoshida T, Nguyen M, Zhang L, Lu B, Zhu B, Murray K, Mineur Y, Zhang C, Xu D, Lin E, Luchsinger J, Bhatta S, Waizman D, Coden M, Ma Y, Israni-Winger K, Russo A, Wang H, Song W, Al Souz J, Zhao H, Craft J, Picciotto M, Grutzendler J, Distasio M, Palm N, Hafler D, Wang A. The subfornical organ is a nucleus for gut-derived T cells that regulate behaviour. Nature 2025, 1-10. PMID: 40437096, DOI: 10.1038/s41586-025-09050-7.Peer-Reviewed Original ResearchMeningeal T cellsCentral nervous systemT cellsSubfornical organCD4 T cellsInnate immune compartmentGut-brain axisSteady-state brainGut microbiotaSpecialized immune cellsCentral nervous system homeostasisAdaptive immune systemBiological functionsImmune compartmentGut-derived T cellsImmune cellsWhite adiposeImmune systemNervous systemAdipose tissueComposition of adipose tissueGastrointestinal tissuesWell-characterizedHomeostasisBrain
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply